Overview

* DarioHealth Q2 2025 revenue fell 14% yr/yr to $5.4 mln, missing expectations

* Operating loss for Q2 narrowed by 43% yr/yr due to operational efficiencies

* Co secured $5 mln new CARR, with $53 mln pipeline of opportunities

Outlook

* Dario expects cashflow breakeven by end of 2026 to early 2027

* Company anticipates $53 mln in commercial opportunities pipeline

* AI-driven efficiencies to cut operating expenses by 15% in 12-15 months

Result Drivers

* REVENUE DECLINE - Co attributes revenue decline to shift from one-time revenues to building ARR and delays in onboarding new clients

* GROSS MARGIN IMPROVEMENT - Gross margin increased to 55% from 44% yr/yr due to changes in revenue mix and lower amortization expenses

* OPERATING EFFICIENCIES - Operating expenses decreased by 36% yr/yr due to AI-driven process optimizations and post-merger integration activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $5.40 $6.91

Revenue mln mln (3

Analysts

)

Q2 Net Miss -$12.99 -$10.80

Income mln mln (3

Analysts

)

Q2 Miss -$9.20 -$8.72

Operatin mln mln (2

g Income Analysts

)

Q2 Gross $3 mln

Profit

Q2 $12.20

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for DarioHealth Corp ( DRIO ) is $2.25, about 77.6% above its August 11 closing price of $0.50

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)